The treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized
over the past two decades, bringing forth an era in which more than a dozen therapeutic …

The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the
past several years with the emergence of molecularly targeted therapies. With previous …

Purpose: This study aimed to carry out a comprehensive analysis of genetic and epigenetic
changes of the von Hippel Lindau (VHL) gene in patients with conventional (clear cell) renal …

The availability of agents directly targeting tumorigenic and angiogenic pathways has
significantly improved the outcomes of patients with advanced renal cell carcinoma (RCC) in …

The von Hippel-Lindau (VHL) gene is inactivated frequently in sporadic clear-cell renal cell
carcinomas (ccRCCs) by genetic alteration (mutation, loss of heterozygosity, or promoter …

Abstract Von Hipple–Lindau gene (VHL) inactivation represents the most frequent
abnormality in clear cell renal cell carcinoma (ccRCC). Hypoxia-inducible factor-1α (HIF-1α) …

Background The prognostic value of molecular markers in renal cell carcinoma has been
investigated in several studies. Although their value is still not confirmed, various proteins …

PURPOSE: To estimate the prevalence and importance of GSTT1, GSTM1, and CYP1B1
genotypes in renal cell carcinoma (RCC), and to identify their value as a prognostic factor …

With the recent advances in targeted therapies, biomarkers in renal cell carcinoma (RCC)
continue to be developed. Historically, information regarding prognosis has come from …

Objective. This study aimed to evaluate the usefulness of carbonic anhydrase IX (CA-IX)
expression in clear cell renal cell carcinoma (CCRCC) using two different techniques to …